Protara Therapeutics, Inc.
TARA
$6.19
$0.284.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -18.17% | -57.26% | -7.38% | -24.93% | -13.78% |
| Total Depreciation and Amortization | 4.76% | 18.07% | 0.00% | -23.36% | 6.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.20% | -38.49% | -33.76% | -46.13% | -36.65% |
| Change in Net Operating Assets | -111.15% | 314.68% | -394.42% | 1,199.12% | -1.34% |
| Cash from Operations | -47.64% | -59.36% | -41.76% | -6.99% | -28.55% |
| Capital Expenditure | 50.00% | 60.00% | -- | -- | 78.38% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 77.87% | -1,690.03% | -352.42% | 54.98% | -558.02% |
| Cash from Investing | 77.86% | -1,720.48% | -352.61% | 54.98% | -560.80% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.97% | -94.07% | -- | -- | -- |
| Repurchase of Common Stock | -- | 100.00% | -143.42% | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -100.00% | -- | -- | -- |
| Cash from Financing | -- | -99.98% | 2,376.32% | -- | 100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 49.91% | -260.55% | -664.15% | 1,808.58% | -17,911.43% |